These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16239394)

  • 1. How does B cell depletion therapy work, and how can it be improved?
    Clark EA; Ledbetter JA
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv77-80. PubMed ID: 16239394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders.
    Edwards JC; Leandro MJ; Cambridge G
    Biochem Soc Trans; 2002 Aug; 30(4):824-8. PubMed ID: 12196207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.
    Pers YM; Jorgensen C
    Immunotherapy; 2016 Sep; 8(9):1091-6. PubMed ID: 27485081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis.
    Edwards JC; Leandro MJ; Cambridge G
    Rheum Dis Clin North Am; 2004 May; 30(2):393-403, viii. PubMed ID: 15172048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B cells as a therapeutic target in autoimmune disease.
    Goronzy JJ; Weyand CM
    Arthritis Res Ther; 2003; 5(3):131-5. PubMed ID: 12723978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No B cells--no active RA? Advances in B cell depletion in RA--repeated therapy under conditions of clinical practice.
    Dörner T; Burmester GR
    Rheumatology (Oxford); 2007 Apr; 46(4):563-4. PubMed ID: 17337751
    [No Abstract]   [Full Text] [Related]  

  • 7. B-cell depletion in autoimmune diseases. Advances in autoimmunity.
    Guzman Moreno R
    Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for B-cell-targeted therapy in autoimmune disease.
    Edwards JC; Cambridge G
    Rheumatology (Oxford); 2005 Feb; 44(2):151-6. PubMed ID: 15509628
    [No Abstract]   [Full Text] [Related]  

  • 9. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?
    Stohl W; Looney RJ
    Clin Immunol; 2006 Oct; 121(1):1-12. PubMed ID: 16697258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response.
    Adlowitz DG; Barnard J; Biear JN; Cistrone C; Owen T; Wang W; Palanichamy A; Ezealah E; Campbell D; Wei C; Looney RJ; Sanz I; Anolik JH
    PLoS One; 2015; 10(6):e0128269. PubMed ID: 26047509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20.
    Edwards JC; Leandro MJ; Cambridge G
    Curr Dir Autoimmun; 2005; 8():175-92. PubMed ID: 15564721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cell therapies for rheumatoid arthritis: beyond B cell depletion.
    Calero I; Nieto JA; Sanz I
    Rheum Dis Clin North Am; 2010 May; 36(2):325-43. PubMed ID: 20510237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated B-cell depletion in clinical practice.
    Edwards JC; Cambridge G; Leandro MJ
    Rheumatology (Oxford); 2007 Sep; 46(9):1509. PubMed ID: 17623746
    [No Abstract]   [Full Text] [Related]  

  • 14. Rehabilitation or the death penalty: autoimmune B cells in the dock.
    Dahal LN; Cragg MS
    Eur J Immunol; 2015 Mar; 45(3):687-91. PubMed ID: 25639261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenic functions of B cells in autoimmune diseases: IFN-γ production joins the criminal gang.
    Fillatreau S
    Eur J Immunol; 2015 Apr; 45(4):966-70. PubMed ID: 25727209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell inhibition by cross-linking CD79b is superior to B-cell depletion with anti-CD20 antibodies in treating murine collagen-induced arthritis.
    Brühl H; Cihak J; Talke Y; Rodriguez Gomez M; Hermann F; Goebel N; Renner K; Plachý J; Stangassinger M; Aschermann S; Nimmerjahn F; Mack M
    Eur J Immunol; 2015 Mar; 45(3):705-15. PubMed ID: 25471597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis.
    Leandro MJ
    Arthritis Res Ther; 2009; 11(5):128. PubMed ID: 19818166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
    Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
    J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell reductive therapy in the treatment of autoimmune diseases: a focus on monoclonal antibody treatment of rheumatoid arthritis.
    Tuscano JM; Martin S; Song K; Wun T
    Hematology; 2005 Dec; 10(6):521-7. PubMed ID: 16321818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The humoral response in rheumatoid arthritis and the effect of B-cell depleting therapy].
    Thurlings RM; Vos K; Gerlag DM; Tak PP
    Ned Tijdschr Geneeskd; 2006 Jul; 150(30):1657-61. PubMed ID: 16922350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.